Moderna, Inc. — Director's Dealing 2019

Mar 11, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2019-03-08

Reporting Person: LEE JENNIFER LING (Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-08	Common Stock	A	4780	—	Acquired	4780	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-08	Stock Option (Right to Buy)	$20.93	A	25097	Acquired	2029-03-08	Common Stock (25097)	Direct

Footnotes

F1: 25% of the shares subject to this restricted stock unit award will vest on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2: 25% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.